7 research outputs found
2017 Scientific Consensus Statement: land use impacts on the Great Barrier Reef water quality and ecosystem condition. Chapter 4: management options and their effectiveness
This chapter seeks to answer the following questions:
1. What are the values of the Great Barrier Reef?
2. How effective are better agricultural practices in improving water quality?
3. How can we improve the uptake of better agricultural practices?
4. What water quality improvement can non-agricultural land uses contribute?
5. How can Great Barrier Reef water quality improvement programs be improved?
Each section summarises the currently available peer reviewed literature and comments on implications for management and research gaps.
This chapter has a wider scope than previous Scientific Consensus Statements, including, for the first time, the social and governance dimensions of management and the management of non-agricultural land uses. These new sections are constrained by a lack of Great Barrier Reefâspecific data and information. The relevance of information from other locations must be carefully considered. In comparison, the agricultural practice change and economics sections provide an update on material compiled as part of the 2013 Scientific Consensus Statement.
This report has been confined to peer reviewed literature, which is generally published in books and journals or major reports. There is additional evidence in grey literature, such as project and program reports, that has not been included here. Each section of this chapter has been compiled by a writing team and then revised following a series of review processes
Improving the Pharmacodynamics and In Vivo Activity of ENPP1âFc Through Protein and Glycosylation Engineering
Enzyme replacement with ectonucleotide pyrophosphatase phospodiesteraseâ1 (ENPP1) eliminates mortality in a murine model of the lethal calcification disorder generalized arterial calcification of infancy. We used protein engineering, glycan optimization, and a novel biomanufacturing platform to enhance potency by using a threeâprong strategy. First, we added new Nâglycans to ENPP1; second, we optimized pHâdependent cellular recycling by protein engineering of the Fc neonatal receptor; finally, we used a twoâstep process to improve sialylation by first producing ENPP1âFc in cells stably transfected with human αâ2,6âsialyltransferase (ST6) and further enhanced terminal sialylation by supplementing production with 1,3,4â
O
âBu
3
ManNAc. These steps sequentially increased the halfâlife of the parent compound in rodents from 37Â hours to ~Â 67Â hours with an added Nâglycan, to ~Â 96Â hours with optimized pHâdependent Fc recycling, to ~Â 204Â hours when the therapeutic was produced in ST6âoverexpressing cells with 1,3,4â
O
âBu
3
ManNAc supplementation. The alterations were demonstrated to increase drug potency by maintaining efficacious levels of plasma phosphoanhydride pyrophosphate in ENPP1âdeficient mice when the optimized biologic was administered at a 10âfold lower mass dose less frequently than the parent compoundâonce every 10Â days vs. 3 times a week. We believe these improvements represent a general strategy to rationally optimize protein therapeutics
Recommended from our members
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
We retrospectively analyzed non-small cell lung cancer (NSCLC) patients from a single center treated with pembrolizumab on the KEYNOTE-001 trial and evaluated the association between treatment-related adverse events (trAEs) and clinical outcomes. Investigators reported AEs on trial and graded them according to Common Terminology Criteria for Adverse Events v4.0, labeling them as unlikely, possibly, or probably treatment-related. AEs labeled as possibly/probably related were considered trAEs for this analysis. The relationship between the incidence of a trAE and clinical outcomes was evaluated. Ninety-seven NSCLC patients treated on KEYNOTE-001 at the University of California, Los Angeles were evaluated. Ten percent (85/826) of AEs were trAEs, occurring in 40% (39/97) of patients. The most frequent trAEs were rash (21% patients), fatigue (6% patients), and hypothyroidism (6% patients). The 39 patients that experienced a trAE had increased objective response rate (ORR, 38.5%), progression-free survival (PFS: median, 248 days), and overall survival (OS: median, 493 days), compared with the 58 patients that did not (ORR: 8.9%, PFS: median 60 days, OS: median 144.5 days). The observed association between trAEs and improved clinical outcome persisted when using Cox proportional hazards regression models to assess the confounding effect of covariates and mitigate guarantee-time bias. The association also remained when data were substratified by grade, degree of association, and treatment-related select AE designation. This single-center analysis revealed that trAEs predicted for improved clinical outcome with pembrolizumab, and when controlling for guarantee-time bias and plausible confounders, this association remained. This observed relationship adds to our understanding of anti-PD-1 therapy and could aid clinicians in identifying patients most likely to benefit from therapy. Cancer Immunol Res; 6(3); 288-94. ©2018 AACR